Review
Copyright ©The Author(s) 2017.
World J Gastroenterol. Apr 28, 2017; 23(16): 2854-2869
Published online Apr 28, 2017. doi: 10.3748/wjg.v23.i16.2854
Table 1 Summary of studies compared eradication rates of susceptible guided with emprical threapy for the first line eradication regimen
Ref.MethodsType of therapy
Patient number (n)
Eradication rates; ITT/PP (%)
SGTEmpirical therapySGTEmpirical therapySGTEmpirical therapy
Dong et al[73], 2015E-testBismuth Quadruple Therapy (RpzBAC, RpzBAL, RpzBAF, RpzBAM, RpzBCM)Quadruple Therapy (RpzBAC)454591.1/95.373.3/78.6
Park et al[87], 2014Agar dilüsyonP AC, PAM, PALPAC575794.7/96.471.9/73.2
Martos et al[82], 2014E-testOAC, OAM, OALOAC555094/9467/72
Cosme et al[84], 2015E-testOAL, OAM, OACCT = OACM12218194.2/95.187.2/88.7
Cosme et al[26], 2012E-testOAC, OBMT, OAL, OAM, OAR, OADOAC, OAM, OAL, OML, OMC134113NR/88NR/49
Zhou et al[92],2015E-testRpz/EAC, Rpz/EATzCT = EACTz,350350 TTB88.7/93.377.4/87(TTB)
TTB = BEAC350 CT78.3/87.4(CT)
Lee et al[88], 2013PCRRpzAC, RpzAMRpzAC, RpzAM21861680.7/91.269.5/75.9 (RpzAC)
71.1/79.1 (RpzAM)
Table 2 Eradication rates achieved with susceptible guided therapy as first treatment and rescue treatment
Line of therapyRef.Type of therapyPatients (n)MethodsTailored therapy eradication rates
ITT %PP %
First LineLiu et al[83], 2015RpzBAC, RpzBAF89Real-time PCR98 in RpzBAC group100 in RpzBAC group
92.6 in RpzBAF group94 in RpzBAF group
First LineSugimoto et al[90], 2014RpzAC, RpzAM153PCR96.7 (overall)97.4 (overall)
Third lineLiou et al[89], 2013Sequential triple135PCR and Agar dilution80.782.6
FourthFiorini et al[91], 2013Triple (EAC, EAR)236E-testNR90 in EAC
88.6 in EAR